Vertex Pharmaceuticals (VRTX) EBITDA (2009 - 2026)

Vertex Pharmaceuticals (VRTX) has reported EBITDA for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA rose 80.62% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $4.7 billion (up 730.65% YoY), while the FY2025 annual figure was $4.2 billion, up 1891.88% from the prior year.
• EBITDA came in at $1.1 billion for Q1 2026 at Vertex Pharmaceuticals, down from $1.2 billion in the prior quarter.
• The five-year high for EBITDA was $1.2 billion in Q4 2025, with the low at -$3.5 billion in Q2 2024.
• Average EBITDA over 5 years is $777.5 million, with a median of $1.0 billion recorded in 2022.
• Across the five-year window, EBITDA soared 3019.0% in 2022 and tumbled 442.43% in 2024, its largest moves.
• Year by year, EBITDA stood at $1.0 billion in 2022, then decreased by 4.35% to $988.5 million in 2023, then climbed by 3.79% to $1.0 billion in 2024, then gained by 17.53% to $1.2 billion in 2025, then retreated by 5.62% to $1.1 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $1.1 billion, $1.2 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.